Table 1.
Baseline characteristics of all patients with PsA.
| Patients with PsA (n = 47) | |
|---|---|
| Age, years | 56.4 ± 15.2 |
| Female, % | 53.2 |
| BMI, kg/m2 | 23.6 ± 4.1 |
| Disease duration for psoriasis, months | 169.9 ± 164.1 |
| Disease duration for PsA, months | 90.8 ± 123.6 |
| NSAIDs use rate, % | 14.9 |
| MTX use rate, % | 19.1 |
| bDMARDs use rate, % | 14.9 |
| PASE | 45.9 ± 15.2 |
| PASI | 7.2 ± 10.1 |
| DAPSA | 20.4 ± 18.2 |
| DAS28-CRP | 3.23 ± 1.37 |
| mHAQ | 0.47 ± 0.48 |
| SvdH | 12.6 ± 18.6 |
| CRP, mg/dL | 0.90 ± 2.46 |
| MMP-3, ng/mL | 84.35 ± 53.91 |
| Tender entheses count | 1.72 ± 2.62 |
| US active enthesitis count | 3.09 ± 2.55 |
| Tender joint count | 5.93 ± 5.92 |
| Swollen joint count | 2.56 ± 3.92 |
| US arthritis assessment—GS score US arthritis assessment—PD score |
5.00 ± 4.55 2.74 ± 3.74 |
Data are shown as mean ± standard deviation. PsA, psoriatic arthritis; BMI, body mass index, NSAIDs, non-steroidal anti-inflammatory drugs; MTX, methotrexate; bDMARDs, biological disease-modifying antirheumatic drugs; PASE, Psoriatic Arthritis Screening and Evaluation, PASI, Psoriasis Area Severity Index; DAPSA, Disease Activity in Psoriatic Arthritis; DAS, Disease Activity Score; CRP, C-reactive protein; mHAQ, modified Health Assessment Questionnaire; SvdH, Sharp–van der Heijde scoring method for PsA; MMP-3, matrix metalloproteinase 3; GS, grayscale; PD, power Doppler.